GeneDx rises on Q4 beats, reiterating 2026 revenue guidance
Source: SeekingAlpha
2026-02-23 13:01:43 ET
More on GeneDx Holdings
- GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript
- GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- GeneDx outlines $540M–$555M 2026 revenue target as company accelerates market expansion with new sales force
- GeneDx Holdings Non-GAAP EPS of $0.18 beats by $0.06, revenue of $121M beats by $0.56M
Read the full article on Seeking Alpha
For further details see:
GeneDx rises on Q4 beats, reiterating 2026 revenue guidance
GeneDx Holdings Corp.
NASDAQ: WGS
WGS Trading
5.88% G/L:
$85.34 Last:
489,787 Volume:
$84.29 Open:
WGS Latest News
March 09, 2026 08:30:00 am
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity(TM) and Real-World Genomic Leadership
February 26, 2026 05:00:14 pm
GeneDx's Chief Operating Officer Sold Nearly 6,000 Shares. Is the Stock a Buy or Sell?
WGS Stock Data
$2,739,577,040
20,348,831
0.11%
111
N/A
Medical Diagnostics & Screening
Healthcare
US
Stamford
